Truvestments Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-9,849
Closed -$69.3K – 583
2026
Q2
$69.3K Hold
9,849
– – 0.01% 476
2026
Q1
$66.7K Hold
9,849
– – 0.01% 460
2025
Q4
$78.4K Buy
9,849
+5,210
+112% +$39K 0.01% 381
2025
Q3
$31.9K Buy
4,639
+627
+16% +$3.4K 0.01% 512
2025
Q2
$15.6K Buy
+4,012
New +$15.6K ﹤0.01% 581

Other funds holding DMAC

Truvestments Capital's DMAC Position: Q3 2026 in Review

Truvestments Capital sold out of DiaMedica Therapeutics (DMAC) in Q3 2026, closing a stake of 9,849 shares — an estimated $69.3K sold.

Truvestments Capital first reported a position in DMAC in Q2 2025 and held it in 5 quarters. The position peaked at $78.4K in Q4 2025. 97 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

  • Truvestments Capital reported no remaining DiaMedica Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Truvestments Capital sold 9,849 DiaMedica Therapeutics shares in Q3 2026, an estimated $69.3K.
  • Truvestments Capital first reported a position in DiaMedica Therapeutics in Q2 2025 and held it in 5 quarters.
  • Truvestments Capital's DiaMedica Therapeutics position peaked at $78.4K in Q4 2025.
  • 97 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on Truvestments Capital's 13F filing for Q3 2026, filed 16 Nov 2026.